COVID-19 Update: AAHA staff is currently working remotely and will support our members virtually. All orders are currently shipping as normal.
Click here for more information.

Footnotes

  1. Cytoxan; Bristol-Myers Squibb Co., Princeton, NJ
  2. Palladia; Zoetis, Florham Park, NJ
  3. Kinavet-CA1; AB Science, Chatham, NJ
  4. ONCEPT; Merial, Ltd., Duluth, GA
  5. Cerenia; Zoetis, Florham Park, NJ
  6. Zofran; GlaxoSmithKline, Research Triangle Park, NC
  7. Anzemet; Sanofi-Aventis, Bridgewater, NJ
  8. Hill’s Prescription Diet n/d Canine, Hill’s Prescription Diet a/d canine/ feline critical care; Hill’s Pet Nutrition, Inc., Topeka, KS
  9. Iam’s Veterinary Formula Maximum Calorie canine/feline; Mars Petcare, Brussels, Belgium
  10. Elspar; Merck&Co., Inc., West Point, PA
  11. BD Phaseal; Becton, Dickinson&Co., Franklin Lakes, NJ
  12. Equashield CSTD; Equashield, LLC, Port Washington, NY
  13. OnGuard; B. Braun Medical, Inc., Bethlehem, PA
  14. ChemoLock and ChemoClave; ICU Medical, Inc., San Clemente, CA

References

  1. Fleming JM, Creevy KE, Promislow DE. Mortality in North American Dogs from 1984 to 2004: An investigation into age-, size- and breedrelated causes of death. J Vet Intern Med 2011;25(2):187–198.
  2. Chun R, Garrett LD, Vail DM. Cancer chemotherapy. In: Withrow& MacEwen’s Small Animal Clinical Oncology. 4th ed. St. Louis: Elsevier Saunders; 2006:163–92.
  3. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60(7):1878–86.
  4. Emmenegger U, Man S, Shaked Y, et al. A comparative analysis of lowdose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 2004;64(11):3994–4000.
  5. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nature reviews 2004;4(6):423–36.
  6. Mancuso P, Colleoni M, Calleri A, et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006;108(2):452–9.
  7. Biller B. Metronomic chemotherapy ion veterinary patients with cancer: Rethinking the targets and strategies of chemotherapy. Vet Clin North Am Small Anim Pract 2014;44(5):817–29.
  8. Burton JH, Mitchell L, Thamm DH, et al. Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma. J Vet Intern Med 2011;25(4):920–26.
  9. Lana S, U’ren L, Plaza S, et al. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med 2007(4) 21:764–9.
  10. Elmslie RE, Glawe P, Dow SW. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. J Vet Intern Med 2008(6) 22:1373–9.
  11. Tripp CD, Fidel J, Anderson CL, et al. Tolerability of metronomic administration of lomustine in dogs with cancer. J Vet Intern Med 2011; 25(2):278–84.
  12. London CA. Small molecule inhibitors in veterinary oncology practice. Vet Clin North Am Small Anim Pract 2014;44 (5)893–908.
  13. Mitchell L, Thamm DH, Biller BJ. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. J Vet Intern Med 2012;26(2):355–62.
  14. Rau SE, Barger LG, Burgess KE. Efficacy of maropitant in the prevention of delayed vomiting associated with administraiton of doxorubicin to dogs. J Vet intern Med 2010;24(6):1452–7.
  15. Mauldin GE. Supportive care for the cancer patient: Nutritional management of the cancer patient. In: Withrow&MacEwen’s Small Animal Clinical Oncology. 4th ed. St. Louis: Elsevier Saunders; 2006:307–26.
  16. Epstein M, Rodan I, Griffenhagen G, et al. 2015 AAHA/AAFP Pain Management Guidelines for Dogs and Cats. J Am Anim Hosp Assoc 2015;51(2):67–84.
  17. Farrelly J, McEntee MC. A survey of veterinary radiation facilities in 2010. Vet Radiol Ultrasound 2014;55(6):638–43.
  18. LaRue SM, Custis JT. Advances in veterinary radiation therapy: targeting tumors and improving patient comfort. Vet Clin North Am Small Anim Pract 2014;44(5):909–23.
  19. McEntee MC, Steffey M, Dykes NL. Use of surgical hemoclips in radiation treatment planning. Vet Radiol Ultrasound. 2008;49(4):395–9.
  20. LaRue SM, Custis JT. Advances in veterinary radiation therapy: targeting tumors and improving patient comfort. Vet Clin North Am
  21. LaRue SM, Gillette EL. Radiation Therapy. In: Withrow&MacEwen’s Small Animal Clinical Oncology. 4th ed. St. Louis: Elsevier Saunders, 2006:193–210.
  22. McEntee MC. Portal radiography in veterinary radiation oncology: options and considerations. Vet Radiol Ultrasound. 2008;49(1 Suppl 1): S57–S61.
  23. Nguyen SM, Thamm DH, Vail DM, et al. Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol 2015;13(3):176–83.
  24. Vail DM, Michaels GM, Khanna C, et al. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0) – a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol 2010;8(1):28–37.
  25. London CA. Small molecule inhibitors in veterinary oncology practice. Vet Clin North Am Small Anim Pract 2014 44(5):893–908.
  26. McMillan SK, Boria P, Moore GE, et al. Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc 2011;239(8):1084–9.
  27. London CA, Gardner HL, Mathie T, et al. Impact of toceranib / piroxicam/cyclophosphamide maintenance therapy on outcome of dogs with appendicular osteosarcoma following amputation and carboplatin chemotherapy: A multi-institutional study. PLoS One 2015;29:10(4): e0124889.
  28. Connor TH, MacKenzie BA, DeBord DG, et al. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH); 2014.
  29. Power L, Polovich M. Safe Handling of Hazardous Drugs: Reviewing Standards for Worker Protection. Pharmacy Practice News 2011. http:// www.pharmacypracticenews.com/download/safe_handling_ppn0311_ wm.pdf. Accessed April 10, 2015.
  30. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm 2006;63(1):1172– 1193.
  31. U.S. Pharmacopeial Convention. (800) Hazardous Drugs Handling in Healthcare Settings. http://www.usp.org/sites/default/files/usp_pdf/EN/ m7808_pre-post.pdf. Accessed March 4, 2015.
  32. Connor TH, Sessink PJ, Harrison BR, et al. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studies. Am J Health-Syst Pharm 2005;62(5): 475–484
  33. Section 14 – Cytotoxic Spills, Extravasation, and Other Incidents. J Oncol Pharmacy Pract 2007;13(3 suppl):62–65.
  34. Problem Drugs. College of Veterinary Medicine, Veterinary Clinical Pharmacology Laboratory, Washington State University. vcpl.vetmed. wsu.edu/problem-drugs. Accessed December 10, 2015.
  35. Affected Breeds. College Of Veterinary Medicine, Veterinary Clinical Pharmacology Laboratory, Washington State University. vcpl.vetmed. wsu.edu/affected-breeds. Accessed December 10, 2015.
  36. Fidalgo JA, Pe´rez L, Garc─▒´a Fabregat A, et al. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol 2012;23(suppl 7):vii167–vii173.
  37. ISMP’s List of Confused Drug Names. Institute for Safe Medicine Practices. http://www.ismp.org/tools/confuseddrugnames.pdf. Accessed March 3, 2015.
  38. ISMP’s List of Error-Prone Abbreviations, Symbols, and Dose Designations. Institute for Safe Medication Practices. http://www. ismp.org/tools/errorproneabbreviations.pdf. Accessed March 3, 2015.
  39. Frankel RM. Pets, vets, and frets: what relationship-centered care research has to offer veterinary medicine. J Vet Med Educ 2006;33(1):20–7.
  40. Armstrong J, Holland J. Surviving the stresses of clinical oncology by improving communication. Oncology 2004;18(3):363–8.
  41. Baile WF, Aaron J. Patient-physician communication in oncology: past, present, and future. Curr Opin Oncol 2005;17(4):331–5.
  42. Bredart A, Bouleuc C, Dolbeault S. Doctor-patient communication and satisfaction with care in oncology. Curr Opin Oncol 2005;17(4):351–4.
  43. Carney HC, Little S, Brownlee-Tomasso D, et al. AAFP and ISFM feline friendly nursing care guidelines. J Feline Med Surg 2012;14(5): 337–349.